USANA Health Sciences Inc (USNA) — 分析摘要
USANA Health Sciences Inc(USNA)的市值为276.22百万美元,最近一年的营收同比增长了+8.3%。净利润率为1.2%。当前市盈率为-12.5倍。
核心要点
- 营收同比变化+8.3%
- 净利润率1.2%
- 市盈率-12.5倍
与MEDICINAL CHEMICALS & BOTANICAL PRODUCTS板块的其他公司相比,USNA的营收增长为+8.3%,市盈率为-12.5倍。
USANA Health Sciences Inc (USNA)
前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -2.6x — 盈利不足以覆盖利息支出
净利润由上一期盈利转为亏损。
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
行业
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
员工人数
1,570
总部
SALT LAKE CITY, UT
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。